Fulcrum Therapeutics, Inc. (FULC)
Chart Events
Performance Outlook
| Previous Close | 8.74 |
| Open | 8.51 |
| Bid | 8.67 x 1400 |
| Ask | 8.72 x 900 |
| Day's Range | 8.41 - 8.84 |
| 52 Week Range | 6.85 - 33.10 |
| Volume | |
| Avg. Volume | 759,721 |
| Market Cap | 353.18M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.34 |
| Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.88 |
- GlobeNewswire
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic measures from the ongoing 6 mg dose cohort of FTX-6058 in adults with sickle cell disease (SCD) - Investor webcast to be hosted on June 10th at 8 a.m. EDT CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving th
- Zacks
Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus
Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
- Simply Wall St.
What Does The Future Hold For Fulcrum Therapeutics, Inc. (NASDAQ:FULC)? These Analysts Have Been Cutting Their Estimates
The analysts covering Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) delivered a dose of negativity to shareholders today...
